Cytochrome P450 1B1: a novel anticancer therapeutic target.
Cytochrome P450 (CYP)1B1 is overexpressed in tumor cells and is also recognized as a biomarker of the tumor phenotype. This review highlights the tremendous potential of this enzyme as a novel cancer therapeutic target. The range of therapeutic strategies including immunotherapeutics, CYP1B1-activated prodrugs and CYP1B1 inhibitors, that are currently being developed to exploit the presence and activity of CYP1B1 in tumor cells is outlined. The therapeutic strategy, which is at the most advanced stage of development, is a CYP1B1-based vaccine which has already successfully completed a Phase I clinical trial.
Robert Gordon University, School of Pharmacy, Schoolhill, Aberdeen, AB10 1FR, UK. m.mcfadyen@rgu.ac.uk
Morag C E
MC
McFadyen
Graeme I
GI
Murray
D000970:Antineoplastic Agents / Q000378:metabolism / Q000627:therapeutic use*; D001189:Aryl Hydrocarbon Hydroxylases / Q000037:antagonists & inhibitors*; D065633:Cytochrome P-450 CYP1B1; D004791:Enzyme Inhibitors / Q000627:therapeutic use; D005544:Forecasting; D006801:Humans; D007167:Immunotherapy; D009369:Neoplasms / Q000201:enzymology / Q000628:therapy*; D011355:Prodrugs
D000970:Antineoplastic Agents; D004791:Enzyme Inhibitors; D011355:Prodrugs; D001189:Aryl Hydrocarbon Hydroxylases; C585496:CYP1B1 protein, human; D065633:Cytochrome P-450 CYP1B1